| Literature DB >> 25151961 |
M H Lopes1, T G Santos2, B R Rodrigues2, N Queiroz-Hazarbassanov2, I W Cunha3, A P Wasilewska-Sampaio2, B Costa-Silva2, F A Marchi4, L F Bleggi-Torres5, P I Sanematsu6, S H Suzuki6, S M Oba-Shinjo7, S K N Marie7, E Toulmin8, A F Hill8, V R Martins9.
Abstract
Glioblastomas (GBMs) are resistant to current therapy protocols and identification of molecules that target these tumors is crucial. Interaction of secreted heat-shock protein 70 (Hsp70)-Hsp90-organizing protein (HOP) with cellular prion protein (PrP(C)) triggers a large number of trophic effects in the nervous system. We found that both PrP(C) and HOP are highly expressed in human GBM samples relative to non-tumoral tissue or astrocytoma grades I-III. High levels of PrP(C) and HOP were associated with greater GBM proliferation and lower patient survival. HOP-PrP(C) binding increased GBM proliferation in vitro via phosphatidylinositide 3-kinase and extracellular-signal-regulated kinase pathways, and a HOP peptide mimicking the PrP(C) binding site (HOP230-245) abrogates this effect. PrP(C) knockdown impaired tumor growth and increased survival of mice with tumors. In mice, intratumor delivery of HOP230-245 peptide impaired proliferation and promoted apoptosis of GBM cells. In addition, treatment with HOP230-245 peptide inhibited tumor growth, maintained cognitive performance and improved survival. Thus, together, the present results indicate that interfering with PrP(C)-HOP engagement is a promising approach for GBM therapy.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25151961 DOI: 10.1038/onc.2014.261
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867